A neuroblastoma-specific panel using NGS could be developed to identify more comprehensive genomic information to molecularly treat and predict prognosis with sophistication based on genomic characteristics such as MYCN, TERT, ATRX, ALK, ARID1, and telomere length. The gene discussed is ALK; the disease is neuroblastoma.